<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33226405</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>13</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Retinal Spheroids and Axon Pathology Identified in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>30</StartPage><MedlinePgn>30</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.61.13.30</ELocationID><Abstract><AbstractText Label="PURPOSE">To determine whether patients with amyotrophic lateral sclerosis (ALS) show retinal axon pathology.</AbstractText><AbstractText Label="METHODS">Postmortem eyes from 10 patients with ALS were sectioned and compared with 10 age-matched controls. Retinal sections were evaluated with periodic acid Schiff and phosphorylated (P-NF) and nonphosphorylated (NP-NF) forms of neurofilament with SMI 31 and 32 antibodies. Spheroids identified in the retinal nerve fiber layer were counted and their overall density was calculated in central, peripheral, and peripapillary regions. P-NF intensity was quantified. Morphometric features of ALS cases were compared with age-matched controls using the exact Wilcoxon matched-pairs signed-rank test.</AbstractText><AbstractText Label="RESULTS">Distinct periodic acid Schiff-positive round profiles were identified in the retinal nerve fiber layer of patients with ALS and were most commonly observed in the peripapillary and peripheral retina. The density of periodic acid Schiff-positive spheroids was significantly greater in patients with ALS compared with controls (P = 0.027), with increased density in the peripapillary region (P = 0.047). Spheroids positive for P-NF and NP-NF were detected. P-NF-positive spheroid density was significantly increased in patients with ALS (P = 0.004), while the density of NP-NF spheroids did not differ significantly between ALS and control groups (P &gt; 0.05). P-NF immunoreactivity in the retinal nerve fiber layer was significantly greater in patients with ALS than in controls (P = 0.002).</AbstractText><AbstractText Label="CONCLUSIONS">Retinal spheroids and axon pathology discovered in patients with ALS, similar to hallmark findings in spinal cord motor neurons, point to disrupted axon transport as a shared pathogenesis. Retinal manifestations detected in ALS suggest a novel biomarker detectable by noninvasive retinal imaging to help to diagnose and monitor ALS disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Kieran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology &amp; Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin Mohammed Amin</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology &amp; Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physics, Faculty of Science, Ryerson University, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Neeru</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology &amp; Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glaucoma &amp; Nerve Protection Unit, St. Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology &amp; Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Hyacinth</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Y&#xfc;cel</LastName><ForeName>Yeni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology &amp; Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physics, Faculty of Science, Ryerson University, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmic Pathology Laboratory, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedical Engineering, Science and Technology (iBEST), St. Michael's Hospital, Ryerson University, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mechanical Engineering, Faculty of Engineering and Architectural Science, Ryerson University, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009412" MajorTopicYN="N">Nerve Fibers</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>K. Sharma,</b> None; <b>M. Amin Mohammed Amin,</b> None; <b>N. Gupta,</b> None; <b>L. Zinman,</b> None; <b>X. Zhou,</b> None; <b>H. Irving,</b> None; <b>Y. Y&#xfc;cel,</b> None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>23</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33226405</ArticleId><ArticleId IdType="pmc">PMC7691787</ArticleId><ArticleId IdType="doi">10.1167/iovs.61.13.30</ArticleId><ArticleId IdType="pii">2771989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017; 377(2): 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol. 2017; 30(6): 599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">28914734</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura MC, Novaes MR, Eduardo EJ, Zago YS, Freitas Rdel N, Casulari LA. Prognostic factors in amyotrophic lateral sclerosis: a population based study. PLoS One. 2015; 10(10): e0141500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627754</ArticleId><ArticleId IdType="pubmed">26517122</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. .. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatr. 2010; 81(4): 385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al. .. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006; 253(12): 1642&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330(9): 585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019; 39(2): 733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol. 2007; 6(10): 913&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">17884681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. .. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009; 10(5-6): 310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Byrne S, et al. .. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013; 80(17): 1590&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. .. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(3-4): 153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, et al. .. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatr. 2012; 83(1): 102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chio A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016; 15(11): 1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis. Biomark Med. 2018; 12(7): 693&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">29856233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder DW, Kurland LT, Offord KP, Beard CM. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology. 1986; 36(4): 511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014; 17(1): 17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci. 2013; 14(3): 161&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019; 13: 532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Krizus A, Martinoli MG, et al. .. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994; 3(10): 1757&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Nilsson P, et al. .. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999; 8(2): 157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al. .. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018; 97(6): 1268&#x2013;1283.e1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, Muller K, et al. .. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018; 141(3): 688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, Jonnakuty C, LaMonte BH, et al. .. Mutant dynactin in motor neuron disease. Nat Genet. 2003; 33(4): 455&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, Sedlmeier R, Meyer T, et al. .. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004; 63(4): 724&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Ticozzi N, Fallini C, et al. .. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014; 84(2): 324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CH, Fallini C, Ticozzi N, et al. .. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012; 488(7412): 499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Vance C, Scotter EL, et al. .. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015; 36(3): 1602.e17&#x2013;1602.e27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357530</ArticleId><ArticleId IdType="pubmed">25499087</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, et al. .. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014; 81(3): 536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin KR, Godena VK, Hewitt VL, Whitworth AJ.. Axonal transport defects are a common phenotype in Drosophila models of ALS. Hum Mol Genet. 2016; 25(12): 2378&#x2013;2392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181624</ArticleId><ArticleId IdType="pubmed">27056981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci USA. 2010; 107(47): 20523&#x2013;20528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996651</ArticleId><ArticleId IdType="pubmed">21059924</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller A, Bauer CS, Cohen RN, Webster CP, De Vos KJ. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum Mol Genet. 2017; 26(23): 4668&#x2013;4679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886184</ArticleId><ArticleId IdType="pubmed">28973175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984; 43(5): 471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">6540800</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbo M, Hays AP.. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol. 1992; 51(5): 531&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">1381416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouleau GA, Clark AW, Rooke K, et al. .. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol. 1996; 39(1): 128&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">8572658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M.. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology. 1996; 47(2): 535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Tu P, Abtahian F, Trojanowski JQ, Lee VM. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol. 1997; 139(5): 1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140205</ArticleId><ArticleId IdType="pubmed">9382875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon LA, LaMonte BH, Wallace KE, Weber N, Kalb RG, Holzbaur EL. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport. 2005; 16(6): 533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812301</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW.. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999; 2(1): 50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant HC, Veeranna Grant P. Regulation of axonal neurofilament phosphorylation. Curr Top Cell Regul. 2000; 36: 133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10842750</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang YM, Chiong F, Kuznetsov D, Kasarskis E, Geula C. Motor neurons are rich in non-phosphorylated neurofilaments: cross-species comparison and alterations in ALS. Brain Res. 2000; 861(1): 45&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">10751564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberger LA, Sternberger NH.. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci USA. 1983; 80(19): 6126&#x2013;6130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534374</ArticleId><ArticleId IdType="pubmed">6577472</ArticleId></ArticleIdList></Reference><Reference><Citation>Delisle MB, Carpenter S. Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci. 1984; 63(2): 241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">6538591</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien JP. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol. 1995; 73(9-10): 593&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">8714677</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter S. Proximal axonal enlargement in motor neuron disease. Neurology. 1968; 18(9): 841&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">4176657</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz DG, Greene C, Perl DP, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol. 1988; 47(1): 9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">3334727</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, Dodson A, Swash M, Brion JP, Anderton BH. Cytoskeletal abnormalities in motor neuron disease. An immunocytochemical study. Brain. 1989; 112(Pt 2): 521&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">2706443</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama S, Bouldin TW, Suzuki K. Immunocytochemical and ultrastructural studies of upper motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol. 1992; 83(5): 518&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">1320322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yucel Y, Gupta N.. Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog Brain Res. 2008; 173: 465&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">18929128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu DY, Cringle SJ, Balaratnasingam C, Morgan WH, Yu PK, Su EN. Retinal ganglion cells: energetics, compartmentation, axonal transport, cytoskeletons and vulnerability. Prog Retin Eye Res. 2013; 36: 217&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">23891817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri N, Bell BA, Bonilha VL, Hollyfield JG. Imaging human postmortem eyes with SLO and OCT. Adv Exp Med Biol. 2012; 723: 479&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">22183367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. .. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2): 13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Krenacs L, Krenacs T, Stelkovics E, Raffeld M. Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. In: Oliver C, Jamur MC, eds. Immunocytochemical Methods and Protocols, Methods in Molecular Biology, Vol. 588 Totowa, NJ: Humana Press; 2010;103&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604828</ArticleId><ArticleId IdType="pubmed">20012825</ArticleId></ArticleIdList></Reference><Reference><Citation>Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019; 1897: 289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6749998</ArticleId><ArticleId IdType="pubmed">30539453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberger LA, Harwell LW, Sternberger NH. Neurotypy: regional individuality in rat brain detected by immunocytochemistry with monoclonal antibodies. Proc Natl Acad Sci USA. 1982; 79(4): 1326&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345956</ArticleId><ArticleId IdType="pubmed">7041117</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YJ, Di Nardo A, Kramvis I, et al. .. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008; 22(18): 2485&#x2013;2495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546692</ArticleId><ArticleId IdType="pubmed">18794346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizusawa H, Matsumoto S, Yen SH, Hirano A, Rojas-Corona RR, Donnenfeld H. Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol. 1989; 79(1): 37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">2511732</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMonte BH, Wallace KE, Holloway BA, et al. .. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron. 2002; 34(5): 715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062019</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Farah MH, Ackerley S, et al. .. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci. 2008; 28(9): 1997&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671836</ArticleId><ArticleId IdType="pubmed">18305234</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CH, Roberts EA, Her LS, et al. .. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol. 2003; 161(1): 55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172877</ArticleId><ArticleId IdType="pubmed">12682084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerley S, Thornhill P, Grierson AJ, et al. .. Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments. J Cell Biol. 2003; 161(3): 489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172950</ArticleId><ArticleId IdType="pubmed">12743103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerley S, Grierson AJ, Brownlees J, et al. .. Glutamate slows axonal transport of neurofilaments in transfected neurons. J Cell Biol. 2000; 150(1): 165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185569</ArticleId><ArticleId IdType="pubmed">10893265</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Manfredi, G. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antiox Redox Signal. 2009; 11(7): 1615&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789440</ArticleId><ArticleId IdType="pubmed">19344253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2011; 70(5): 349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. .. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006; 314(5796): 130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Zhai H, Bigio EH, et al. .. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol. 2010; 67(6): 739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376270</ArticleId><ArticleId IdType="pubmed">20517935</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Bigio EH, Zhai H, et al. .. Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol. 2011; 68(8): 1057&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357952</ArticleId><ArticleId IdType="pubmed">21825243</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Warraich ST, Yang S, et al. .. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol Aging. 2012; 33(10): 2527.e3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">22717235</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller BA, Volkening K, Droppelmann CA, Ang LC, Rademakers R, Strong MJ. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol. 2012; 124(5): 733&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">22941224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TY, Klein R, Couper DJ, et al. .. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet. 2001; 358(9288): 1134&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11597667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher JB, Jacobs DA, Markowitz CE, et al. .. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006; 113(2): 324&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406539</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Duggan J, Cordeiro MF. Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res. 2010; 7(1): 3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205667</ArticleId></ArticleIdList></Reference><Reference><Citation>Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain. 2009; 132(Pt 5): 1128&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19336464</ArticleId></ArticleIdList></Reference><Reference><Citation>London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013; 9(1): 44&#x2013;53..</Citation><ArticleIdList><ArticleId IdType="pubmed">23165340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringelstein M, Albrecht P, Sudmeyer M, et al. .. Subtle retinal pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014; 1(4): 290&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292746</ArticleId><ArticleId IdType="pubmed">25590041</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohani M, Meysamie A, Zamani B, Sowlat MM, Akhoundi FH. Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression. J Neurol. 2018; 265(7): 1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">29713825</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonett JM, Huang R, Siddique N, et al. .. Macular sub-layer thinning and association with pulmonary function tests in amyotrophic lateral sclerosis. Sci Rep. 2016; 6: 29187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4935870</ArticleId><ArticleId IdType="pubmed">27383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpe NJ, Simonett J, Fawzi AA, Siddique T. Ophthalmic manifestations of amyotrophic lateral sclerosis (An American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2015; 113: T121&#x2013;T1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731009</ArticleId><ArticleId IdType="pubmed">26877563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P, de Hoz R, Ramirez AI, et al. .. Changes in retinal OCT and their correlations with neurological disability in early ALS patients, a follow-up study. Brain Sci. 2019; 9(12): 337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6955774</ArticleId><ArticleId IdType="pubmed">31771268</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. .. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016; 79(1): 152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>